Madrid (dpa) – Semaglutide-based drugs have quickly become established as treatments for obesity and diabetes, even as signs have emerged that their appetite-suppressing effect can sometimes lead to
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)